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Health effectiveness and cost-effectiveness
of telehealthcare for heart failure: study
protocol for a randomized controlled trial
Simon Lebech Cichosz1*, Lars Holger Ehlers2 and Ole Hejlesen1
Abstract
Background: Several heart failure studies have shown promising results for implementing telehealthcare. These studies
have led to clinical and political interest in telehealthcare as a way to improve heart failure outcomes and lower costs.
However, there is a need for large-scale clinical trials with cost-effectiveness assessments.
Methods/design: The present study is known as the TeleCare North Heart Failure Trial in Denmark. We are studying the
health effectiveness and cost-effectiveness of a telehealth (Telekit) solution compared with usual care for patients with heart
failure. The design is a multicenter, two-arm, parallel-group, nonblinded, superiority randomized controlled trial. Outpatient
healthcare centers will be responsible for recruiting eligible participants (600 participants are expected) for the trial in the
geographic area of the North Denmark Region. Participants are qualified for inclusion if they have been diagnosed
according to national guidelines and are categorized in New York Heart Association class 2, 3, or 4. Patients must have a
permanent residence and be motivated to use telehealth care. The primary outcomes are changes in health-related quality
of life (assessed using the Kansas City Cardiomyopathy Questionnaire, the EuroQol EQ-5D-5L questionnaire, and the Short
Form Health Survey [SF-36]) and in the incremental cost-effectiveness ratio measured from baseline to follow-up. The
secondary outcomes are changes in mortality and in physiological indicators such as blood pressure, pulse, and weight.
Discussion: The TeleCare North Heart Failure Trial is intended to improve the international evidence base for the health
effectiveness and cost-effectiveness of telehealthcare for patients with heart failure. The expectation is that the results of
the trial can be generalized to all municipalities in Denmark and serve as an inspiration for further international research.
Trial registration: ClinicalTrials.gov (NCT02860013). Registered on 28 July 2016.
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Background
Heart failure (HF) is a condition in which the heart muscle
is weakened and is therefore unable to pump blood suffi-
ciently through the body [1, 2]. HF often develops after
other conditions have damaged the heart. Some of the
common causes of HF are coronary heart disease, diabetes,
and high blood pressure. Approximately 26 million people
worldwide are living with HF [3]. In many countries,
population-based studies have found that approximately 1–
2% of people have HF [4–6]. The prognosis for these
patients is not good, with survival rates worse than those
for many types of cancer. Moreover, HF induces great stress
on patients, caregivers, and health systems. Demands on
healthcare services are expected to increase greatly in the
coming years as the number of patient diagnoses rise
because of aging populations and damaging lifestyles. HF
costs an estimated $20 billion each year in the United
States [7]. This total cost includes the cost of medications
to treat HF and the cost of healthcare services [1, 2].
Approximately 60,000–100,000 people in Denmark have
HF, and the incidence of HF is increasing [8]. Moreover,
there are approximately 11,000 hospitalizations per year
for HF in Denmark [8]. The average age of patients with
HF is 72 years, and the incidence increases with age.
Approximately 5% of people over 75 have HF, and the pro-
portion rises to over 10% for people over 85 years of age.
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The prevention of HF-related disease and death needs
to be made a worldwide healthcare priority [1, 2]. Despite
the increasing number of people living with and dying as a
result of HF, awareness of HF is low among the public,
politicians, and some health professionals. Although there
is no cure for HF, many cases are preventable, and most
patients can be treated successfully to improve their qual-
ity of life and survival rate.
Studies of telehealthcare show positive results regarding
health outcomes and quality of life in other patients with
chronic illness [9]. Some studies of feasibility indicate that
the use of telehealthcare may also lower the costs of health-
care [10–13]. Additionally, several studies have shown
promising results for telehealthcare with regard to HF
[14, 15], whereas others have not found an effect [16, 17].
These studies have led to increased political and clinical
attention to telehealthcare as a means of improving out-
comes for patients with HF and lowering costs. However,
there is a need for large-scale clinical trials with cost-
effectiveness assessments in telehealthcare research [14].
In Denmark, healthcare decision makers have agreed to
support the advancement of research into the health
effectiveness and cost-effectiveness of telehealthcare for
patients with HF. As part of the national Danish plan for
the dissemination of telemedicine, a full-scale randomized
trial has been planned for the North Denmark Region
(Region Nordjylland). The North Denmark Region is one
of five regions in Denmark and has healthcare responsibil-
ity for approximately 580,000 people. The project is based
on experiences with and solutions arising from the
TeleCare North COPD trial [18]. The results of the trial
will inform political and clinical decisions regarding how
to implement a telehealthcare solution as a national stand-
ard for HF healthcare in Denmark.
The aims of this trial are separated into two focus areas.
The first area aims to evaluate whether a specific telehealth
solution that is serving as a supplement to usual healthcare
increases quality of life for patients with HF compared with
the quality of life of those receiving usual healthcare alone.
The second area aims to evaluate the cost-effectiveness of
this specific telehealth solution.
Methods/design
Study design
This trial, the TeleCare North Heart Failure Trial in
Denmark, runs from 2016 to December 2017. It is a full-
scale randomized trial with approximately 12 months of
follow-up conducted throughout the whole North
Denmark Region (Fig. 1). All results will be published in
international journals at the end of the trial. (See Additional
file 1 for information regarding the Standard Protocol
Items: Recommendations for Interventional Trials [SPIRIT]
checklist and Additional file 2 for the SPIRIT figure.)
Participants
Inclusion criteria
All patients with HF who may benefit from telehealthcare
are eligible for inclusion. Participants are qualified for
inclusion if they have been diagnosed with HF according
to national guidelines [19] and are categorized in New
York Heart Association class 2, 3, or 4. Patients must have
a permanent residence and be motivated to use telehealth-
care. Motivation is simply assessed by the healthcare
personnel by asking the patient prior to inclusion. More-
over, patients must have a landline or mobile phone, and
they must be able to speak Danish or live with a relative
who speaks Danish. In the latter case, the relative must be
able to help the patient by translating information regard-
ing the use of telehealthcare.
Exclusion criteria
Exclusion criteria are patients without a landline phone,
a mobile phone, or GSM (global system for mobile com-
munications) coverage; patients not able to understand
Danish adequately to complete the questionnaires in the
study. Comorbidity is not an exclusion criterion.
Recruitment
Recruitment takes place in three outpatient healthcare
centers in the North Denmark Region (Aalborg University
Hospital, Vendsyssel Hospital, and Thy-Mors Hospital).
The recruitment includes both newly diagnosed patients
and people with an existing diagnosis of HF. For prag-
matic reasons, recruitment will be consecutive; that is, the
first patients recruited in the project will receive the inter-
vention for a longer time span than those included later in
the process. Clinic staff will be responsible for identifying
potential participants and assessing eligibility when partic-
ipants are in contact with the outpatient healthcare center
for other reasons. The clinical staff are responsible for
Fig. 1 Flow diagram for inclusion, treatment, and follow-up
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telling the patient about the trial, and a printed folder with
information is handed to the patient. All relevant clinical
staff have been informed in meetings by the trial adminis-
tration and have been supplied with written information
about how to identify potential participants and how to
include them.
The outpatient healthcare centers will send signed
informed consent forms, together with the patient
questionnaires and baseline physical measurements, to the
trial administrators. The patient questionnaires include
questions about the participants’ baseline health-related
quality of life (Kansas City Cardiomyopathy Questionnaire
[KCCQ], EuroQol EQ-5D-5L questionnaire, and Short
Form Health Survey [SF-36]) and demographic character-
istics (age, sex, education level, comorbidities, smoking
habits, marital status, and job status). The patient ques-
tionnaires are completed at the outpatient healthcare
center before each patient is assigned to the telehealthcare
(intervention) group or usual healthcare (control) group.
If the patient feels more confident in answering the ques-
tionnaire at home, this will be possible. All primary out-
come data will be entered electronically. Original study
forms will be entered and kept on file.
Randomization
The randomization of patients to either telehealthcare
(intervention) or usual healthcare (control) is performed
at the outpatient center after the patients have signed
informed consent forms. Patient assignments are made
using prepacked bundles of ten envelopes, each with a
card, with assignment of five patients to the intervention
group and five to the control group. Each prepacked
bundle of ten envelopes is shuffled. In the outpatient
healthcare center, a prepacked bundle is chosen to be the
active bundle (i.e., the bundle used for assigning patients
at random). When three envelopes are left in an active
bundle, they are shuffled into a new bundle, and this new
bundle is used as the active bundle.
Intervention
Telekit
The telehealthcare solution, Telekit, is a tablet (Samsung
Galaxy Tab 2; Samsung, Seoul, South Korea) that can be
used to collect data from various external devices and
disease-specific questionnaires. In the present study, the
external devices will collect disease-specific data (blood
pressure, pulse, and weight) from two devices and wire-
lessly transmit this data and the data from questionnaires
to the central clinical system. The two external devices are
a digital blood pressure monitor (Model UA-767 Plus BT-
C; A&D Medical, Tokyo, Japan) and a scale (Precision
Health Scale, UC-321PBT-C; A&D Medical). The software
for the tablet, including the framework for the disease-
specific questionnaires, was developed by Silverbullet
(Aarhus, Denmark; www.opentele.silverbullet.dk). The
questionnaires were constructed by clinical domain
experts in the North Denmark Region. The tablet actively
reminds the patients when it is time to take measurements
and answer questionnaires. The patients, their relatives,
and general practitioners can access the collected data via
a public website (https://www.sundhed.dk/).
Starting the intervention
After randomization, patients with HF in the intervention
group will be contacted (via telephone) by their municipality.
The Telekit (including external devices) is ordered through
Atea (Atea Danmark, Aalborg, Denmark), which delivers
and installs the Telekit at home with the citizen. A nurse
from the HF patient’s municipality will instruct the patient
in the use of the Telekit. The municipality nurse will show
the patient how to use the tablet and how to take physical
measurements and will guide the patient through the Telekit
manual before letting the patient try the Telekit him- or
herself. Patients will be asked to use the scale and blood
pressure monitor daily during the first 2 weeks and one to
two times weekly after the first 2 weeks. A follow-up visit is
scheduled between 2 and 4 weeks after the first appointment
to ensure that the patient uses the Telekit properly.
Measurement assessment
The data, which include measurements (blood pres-
sure, pulse, and weight) and symptom-specific infor-
mation from the tablet questionnaire will be assessed
by a specially trained nurse. The responsibility is
shared between the municipalities and the outpatient
healthcare centers, depending on where the patients
are affiliated.
Data assessment implies that the patient’s data are
seen, interpreted, and evaluated to determine whether
there should be an intervention. The data assessments
will be conducted at fixed intervals (typically one or
two times per week). After each assessment, an ac-
knowledgement will be sent to the patient. If a patient’s
measurements are not received as expected, the patient
will be contacted. The measurements are classified as
being within the normal range or outside the normal
range. These predefined thresholds are adjusted if
necessary during the first 14 days of measurements to
fit the individual patient. The predefined thresholds are
systolic blood pressure 170–100 mmHg, diastolic blood
pressure 90–50 mmHg, pulse 80–55 beats/minute, and
weight ±2 kg.
If the clinician observes abnormal measurements,
several options are available:
1. The clinician can contact the patient and ask for a
new measurement if the measurement is considered
to be less suitable.
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2. The clinician can contact the patient to assess the
patients condition.
3. It is possible to start a self-treatment plan for the
patient.
4. If the clinician judges that the patient is cable of
taking contact to his or her own general practitioner,
the patient is asked to do so.
5. The clinician can contact the patient’s general
practitioner directly.
The intervention needed is always a clinical judgment
based on the patient’s measurement and possibly a sub-
sequently contact with the patient. It should be noted
that the goal is to help the patient understand his or her
own data and thereby empower the patient to take re-
sponsibility for handling the disease.
Outcome assessments
Effectiveness
All outcome measures for the two groups (usual care group
and the intervention group) are collected at baseline and
follow-up. The primary outcome is change in health-related
quality of life (SF-36 and KCCQ) from baseline to follow-
up. SF-36 total score is used as the primary outcome, and
the subscales are used as secondary outcomes. The second-
ary outcomes for effectiveness are changes in the mortality
rate and physiological measurements such as blood pres-
sure, pulse, and weight from baseline to follow-up. Mortal-
ity rate is considered only if enough participants are
included to satisfy the power calculation for this secondary
outcome. The clinical impact of telehealthcare is considered
to be positive if no increase in mortality is observed and if
pulse and blood pressure are lowered.
Cost assessment
The main outcome for cost is the incremental cost-
effectiveness ratio (ICER). The ICER is measured as the
total cost per quality-adjusted life-year (QALY) gained from
baseline to follow-up. It is anticipated that telehealthcare
will increase the participants’ quality of life, but no differ-
ence in mortality is expected. Additionally, it is expected
that telehealthcare will reduce cost, particularly due to a
reduction in the number of admissions/readmissions and
outpatient visits [20].
Sample size
A sample size calculation for effectiveness was performed
using OpenEpi (http://www.openepi.com/Menu/OE_Me-
nu.htm). Conservative estimates were applied for the
minimal clinically important difference (change equal to 5
for the SF-36 physical component summary). With a power
of 80%, groups of equal size, a standard deviation of 15, and
a two-sided p value of <0.05, the required sample size is es-
timated to be at least 284 participants. With an expected
loss to follow-up of 10%, the total required sample size is
estimated to be at least 316 participants.
Statistical methods
Statistical analysis will be conducted using an intention-to-
treat standard. The results will be presented according to
the Consolidated Standards of Reporting Trials (CON-
SORT) statement for randomized clinical trials [21].
Missing data will be assessed to identify patterns of missing
data. Multiple imputation will be used if necessary, and the
observations will be described according to epidemiological
guidelines [22]. If appropriate, an adjustment will be made
for differences between the intervention group and the con-
trol group with regard to baseline characteristics.
Effectiveness
To evaluate effectiveness, differences between the interven-
tion group and the control group with regard to SF-36
scores, mortality rates, and physical measurements from
baseline to follow-up will be analyzed. The outcome will
primarily be analyzed using two-sample paired statistics
(e.g., two-sample paired t test), such that the differences
from baseline to follow-up will be assessed between groups.
Cost assessment
To evaluate economic consequences, a health economic
evaluation will be conducted. This will include the estima-
tion of an ICER to summarize the cost-effectiveness of the
telehealthcare intervention compared with the control
group treatment. The ICER is defined as the difference in
cost between two possible interventions, divided by the
difference in their effect. The ratio represents the average
incremental cost associated with one additional unit of the
measure of effect [22].
The effect measure used for the health economic
evaluation will be QALYs. For all patients, the effect will
be estimated using the EQ-5D-5L questionnaire and the
associated Danish societal weights [23].
A health sector perspective will be used to estimate the
incremental costs. This means that for all patients, all
costs related to healthcare services should be included.
This includes inpatient and outpatient hospital services,
general practitioner services, home care, and prescription
medicine. Costs that are associated only with the research
project that would not occur in a real-life setting will be
excluded. Costs associated with the telehealthcare inter-
vention will be calculated and included in the ICER.
Denmark is internationally known for having a compre-
hensive registration of data on healthcare activities. All citi-
zens have a social security number (CPR) that is registered
when in contact with a public service, such as for health-
care services. Therefore, data may be extracted for individ-
uals to obtain a fairly accurate estimate of that individual’s
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use/cost of healthcare services and/or resources across mu-
nicipalities, general practitioners, and hospitals.
Both deterministic and probabilistic sensitivity analyses
will be conducted to assess the uncertainty of the results.
A Bayesian approach will be applied using bootstrapping
techniques to estimate credibility intervals for the costs
and outcomes. ICERs will be estimated using second-
order Monte Carlo simulations and presented in a scat-
terplot and a cost-acceptability curve [23].
Ethics
The trial has been authorized by the Danish Data Protec-
tion Agency. The study is being conducted in accordance
with the Helsinki declaration. The trial has been presented
to the Ethical Committee for Medical Research in the
North Denmark Region; this committee decided that no
ethical approval was necessary. All study-related informa-
tion will be stored securely at the study site.
Discussion
There is a need for large-scale clinical trials that include
cost-effectiveness assessments in telehealthcare research.
This study, the TeleCare North Heart Failure Trial, is
intended to improve the international evidence base regard-
ing the health effectiveness and cost-effectiveness of
telehealthcare for patients with HF. The TeleCare North
Heart Failure Trial is a large-scale, pragmatic randomized
clinical trial that recruits participants from the entire geo-
graphic area of the North Denmark Region. Changes in
health-related quality of life and health costs are evaluated.
It is expected that the results of the TeleCare North
Heart Failure Trial could be generalized to all regions in
Denmark. Decision makers have indicated that if the
telehealthcare solution in this trial proves to be cost-
effective for patients with HF, it could serve as a national
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